- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approved August 2017). Currently commercialized in the U.S. and Canada.
- Why 4/10
- VABOMERE is an already-approved, marketed drug with no pending regulatory decision or pivotal readout specific to this product in the next ~12 months. The next hard catalyst for CorMedix overall is the REZZAYO sNDA PDUFA (not VABOMERE). VABOMERE is one of several products in a diversified portfolio, so its individual impact on the stock is limited.
VABOMERE is an approved, marketed product with no imminent binary catalyst of its own. The next major catalyst for CorMedix overall is the FDA decision on the REZZAYO sNDA (accepted for Priority Review in October 2026, PDUFA expected in early 2027). Watch for the Phase 2 pediatric study (NCT06672978) primary completion around January 2027, which could support a label expansion for VABOMERE into children, though this is a secondary pipeline item.
Price Chart
Executive Summary
VABOMERE (meropenem and vaborbactam) is an FDA-approved IV antibiotic for complicated urinary tract infections, originally approved in August 2017 for The Medicines Company. It is now owned by CorMedix (CRMD) through the company's $300M acquisition of Melinta Therapeutics in September 2025, which added seven marketed products to CorMedix's portfolio. VABOMERE is a mature, commercial-stage product with no imminent binary catalyst of its own. CorMedix's primary growth driver remains DefenCath, with the next major catalyst being the REZZAYO sNDA for prophylaxis of invasive fungal disease (accepted for Priority Review in October 2026). CorMedix guided FY2026 revenue of $325M-$345M and recently announced a $145M+ acquisition of Heron Therapeutics assets.
How It Works
VABOMERE is an intravenous antibiotic that combines two drugs: meropenem (a broad-spectrum carbapenem antibiotic that kills bacteria by disrupting their cell wall construction) and vaborbactam (a beta-lactamase inhibitor that protects meropenem from being broken down by resistant bacteria). It is used to treat complicated urinary tract infections, including kidney infections, caused by certain drug-resistant bacteria.
Trial Status
VABOMERE is FDA-approved and commercially marketed. A Phase 2 pediatric study (NCT06672978) evaluating meropenem-vaborbactam in children with complicated UTI is active but not recruiting, with estimated primary completion in January 2027. The study is sponsored by Rempex (a Melinta subsidiary).
The Two-Sided Case
Upcoming Catalysts
- Phase 2 pediatric study (NCT06672978) primary completion estimated January 2027, could support pediatric label expansion
- REZZAYO sNDA PDUFA decision (Priority Review accepted October 2026, decision expected early 2027) - the next major company-wide catalyst, though not specific to VABOMERE
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CorMedix Inc. DEFA14A CRMD ·Originating report